Q2 revenue increased 123% to $3,435,835 from same quarter last year
Reported net income of $252,712, compared to a net loss of $353,632 in the same quarter last year
“Our year over year revenue growth for the second quarter was exceptional and further supports our projected revenue and earnings objectives for the full fiscal year,” said Jesse Dylan, GLN President and CEO
It wasn't my primary point of concern, but I did touch on the FDA "modifications" with Don. The FDA is a typical bureaucracy from the way he described it. It seems that just when the compnay thinks they've satisfied all the requirements, another branch will inject itself in the process with a new list of demands to be met....almost like playing whack a mole.
I think they could have worded that news back on July 25th, but it does say they received an approval "pathway", so it seems the FDA might have added a few obstacles along that path, hurdles that still have to be cleared.
On a different note I'm noticing the bid/ask at $1.75 both ways.....obviously that will change, I don't have much faith in pre-market quotes, but hopefully we see a gap up.